Somewhat unexpectedly, the number of NSP12-specific CD4+ T-cell responses directed against individual peptides in an individual did not significantly differ between COVID-19 patients (mean: 12.82 responses; range: 0–25; p > 0.05) and seronegative or pre-pandemic controls (mean: 12.71 responses; range: 0–21) (Figure 2). The gene discussed is CD4; the disease is COVID-19.